Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy

Parker, Chris; Sydes, Matthew R.; Catton, Charles; Kynaston, Howard; Logue, John P; Murphy, Claire; Morgan, Rachel C.; Mellon, K.; Morash, Chris; Parulekar, Wendy R.; Parmar, Mahesh; Payne, Heather; Savage, Colleen; Stansfeld, J. M.; Clarke, Noel W.

doi:10.1111/j.1464-410x.2007.06844.x

Cited by 124 publications

(55 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…'nın çok merkezli eşleştirilmiş kontrollü olgu analizinde adjuvan RT uygulanan veya izlenip PSA düzeyi ≤0,5 ng/ml olduğunda salvaj RT uygulanan pT3N0 olgularda 60 aylık biyokimyasal nüks oranları arasında fark ortaya konamamıştır (adjuvan RT %78,4-salvaj RT %81,8; p=0,9) (27). Bu önemli soruyu cevaplamaya yönelik planlanan Radiotherapy and Combined Androgen Deprivation after Local Surgery (RADICALS), Radiotherapy Adjuvant vs Early Salvage following Radical Prostatectomy (RAVES) ve Groupe d'Etude des Tumeurs Uro-Genitalés (GETUG-17) çalışmalarının sonuçları merakla beklenmektedir (28,29). RADICALS çalışmasında doğrudan adjuvan ve salvaj RT ve ± androjen supresyon tedavisi (6 ay ve 24 ay) karşılaştırılmaktadır.…”

Section: Adjuvan Radyoterapi Mi? Salvaj Radyoterapi Mi?unclassified

AUA/ASTRO 2013 Guidelines for Adjuvant and Salvage Radiation Therapy After Prostatectomy: What are the Yields and the Changes?

Yaman¹

2015

uob

View full text Add to dashboard Cite

Section: Adjuvan Radyoterapi Mi? Salvaj Radyoterapi Mi?unclassified

AUA/ASTRO 2013 Guidelines for Adjuvant and Salvage Radiation Therapy After Prostatectomy: What are the Yields and the Changes?

Yaman¹

2015

uob

View full text Add to dashboard Cite

“…The dose of radiotherapy has also typically increased to 64-66 Gy and is usually delivered with a more precise three-dimensional conformal (3DCRT) or the intensity modulated radiotherapy (IMRT) approach, which may reduce some associated morbidity by sparing the surrounding normal structures. These current standards of care are being investigated in the ongoing Radiotherapy and Androgen Deprivation In Combination After Local Surgery (RADICALS) [12] study, which examines the timing of postoperative radiotherapy with a comparison between adjuvant radiotherapy and observation with early salvage radiation for biochemical failure. RADICALS added a further randomization to investigate the addition and duration of concomitant hormone therapy, which remains another unanswered question in the postoperative setting.…”

Section: Radical Prostatectomymentioning

confidence: 99%

Management of locally advanced prostate cancer

Payne¹

2008

Asian J Androl

Self Cite

View full text Add to dashboard Cite

The management of all stages of prostate cancer is an increasingly complex process and involves a variety of available treatments and many disciplines. Despite prostate-specific antigen (PSA) testing, the presentation of prostate cancer at a locally advanced stage is common in the UK, accounting for one-third of all new cases. There is no universally accepted definition of locally advanced prostate cancer; the term is loosely used to encompass a spectrum of disease profiles that show high-risk features. Men with high-risk prostate cancer generally have a significant risk of disease progression and cancer-related death if left untreated. High-risk patients, including those with locally advanced disease, present two specific challenges. There is a need for local control as well as a need to treat any microscopic metastases likely to be present but undetectable until disease progression. The optimal treatment approach will therefore often necessitate multiple modalities. The exact combinations, timing and intensity of treatment continue to be strongly debated. Management decisions should be made after all treatments have been discussed by a multidisciplinary team (including urologists, oncologists, radiologists, pathologists and nurse specialists) and after the balance of benefits and side effects of each therapy modality has been considered by the patient with regard to his own individual circumstances. This article reviews the current therapy options.

show abstract

“…The role of adjuvant hormone therapy in the postoperative setting is unknown, and subject of an ongoing randomized trial. 6 The evaluation of adjuvant hormone therapy on longterm sexual functioning will be an important endpoint in this trial. Greater use of nerve-sparing procedures in appropriate cases might improve baseline erectile function, but few patients in this series who reported adequate function at baseline retained it with subsequent therapy.…”

Section: Sia Et Almentioning

confidence: 99%

“…The question of whether radiotherapy is best given postoperatively to all at-risk men or selectively to those with evidence of postoperative biochemical progression is unanswered and is being addressed by the ongoing National Cancer Institute of Canada-Clinical Trial Group/Medical Research Council (NCIC-CTG/MRC) PR-13 trial. 6 In the absence of data, the decision to treat or to wait must be made with the patient and take into account the risks and benefits of each approach.…”

Section: Introductionmentioning

confidence: 99%

Treatment-related toxicity and symptom-related bother followingpostoperative radiotherapy for prostate cancer

Sia

Rodrigues²,

Ménard

et al. 2013

CUAJ

Self Cite

View full text Add to dashboard Cite

Introduction: Patients have reported late effects and symptom-related bother following postoperative radiotherapy for prostate cancer. Methods:Patients treated with postoperative radiotherapy were surveyed at a median 56 months after radiotherapy using the Prostate Cancer Radiation Therapy instrument. A retrospective review was undertaken to obtain Radiation Therapy Oncology Group-Late Effects Normal Tissue (RTOG-LENT) toxicity scores at baseline and during follow-up.

show abstract

Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy

Cited by 124 publications

References 15 publications

AUA/ASTRO 2013 Guidelines for Adjuvant and Salvage Radiation Therapy After Prostatectomy: What are the Yields and the Changes?

AUA/ASTRO 2013 Guidelines for Adjuvant and Salvage Radiation Therapy After Prostatectomy: What are the Yields and the Changes?

Management of locally advanced prostate cancer

Treatment-related toxicity and symptom-related bother followingpostoperative radiotherapy for prostate cancer

Contact Info

Product

Resources

About